LY06006 not checked
Luye Pharma Group Ltd. · subcutaneous injection of 60 mg
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Sterile, preservative-free, solution of denosumab packed in 1-mL pre-filled glass syringes for subcutaneous administration.Each syringe contains 60 mg denosumab (60 mg/mL solution) and is intended for single administration once every 6 months.”In the company’s words, NCT05853354 on ClinicalTrials.gov
- Tested for
- Osteoporosis, Postmenopausal
- Main trialPhase 3
- “this comparative clinical study is designed to demonstrate that LY06006 and EU-Prolia have no clinically meaningful differences in clinical efficacy, pharmacodynamic (PD), safety, PK, and immunogenicity in postmenopausal women with osteoporosis.”In the company’s words, NCT05853354 on ClinicalTrials.gov
- Other names
- subcutaneous injection of 60 mg · Denosumab
- Copy of
- Prolia (Amgen)Tested side by side with the original in NCT04973722
Other drugs for Osteoporosis, Postmenopausal
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials15
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 30 Jul 2025 | Comparative Efficacy, Safety, PK, and Immunogenicity Study | |
| Phase 3Unknown | 30 Sep 2021 | A Study to Evaluate the Efficacy and Safety of LY06006 in Postmenopausal Women With Osteoporosis at High Risk for Fracture | |
| Phase 1Unknown | 10 Apr 2021 | A Study to Evaluate LY06006 and Prolia in Healthy Adults | |
| Phase 3Ended | not given | A Phase III, Randomized, Double-Blind, Parallel Group, Multicenter Study to Compare Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of BP16 Versus EU-Prolia® in Women with Post- Menopausal Osteoporosis | |
| Phase 2Ended | not given | NAPO - Novel Approach for Oligospermia | |
| Phase 4Authorised | not given | The effect of denosumab on muscle and strength and insulin sensitivity | |
| Phase 3/4Authorised | not given | DEnosumab for the treatment of FIbrous Dysplasia/McCune-Albright Syndrome in adults (DeFiD): a randomized double-blind placebo-controlled trial | |
| Phase 2Ended | not given | NT-NOA - Novel Treatment of some men with Non-Obstructive Azoospermia Et klinisk interventionsforsøg | |
| Phase 3Authorised | not given | Multicentre, randomized, controlled, open-label, multi-centre medicoeconomic study evaluating the efficacy of adding zoledronic acid or denosumab to Stereotaxic radiotherapy in the treatment of vertebral metastases (ZOSTER) | |
| Phase 3Authorised | not given | BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to Determine the Preventive Effect of Denosumab on Breast Cancer in Women Carrying a BRCA1 Germline Mutation | |
| Phase 2Authorised | not given | A 4-way randomized double-blinded migration (RSA), bone density (DXA), and biomarker study assessing adaptive bone changes and implant fixation and longevity of the new Regenerex Porous Titanium Tibial Tray with different adjuvant medical therapies. | |
| Phase 4Authorised | not given | The DENOCHARCOT trial. Efficacy of treatment with DENOsumab of an acute CHARCOT foot in patients with diabetes. A multicenter, double-blind, randomized, placebo-controlled trial. | |
| Phase 2Authorised | not given | Phase II, multicentre, randomised, open-label trial with MAP +/- denosumab regimen for the treatment of patients with metastatic osteosarcoma | |
| Phase 3Ended | not given | Effects of a single denosumab injection on reduction of total contact cast treatment and consolidation of bone fractures caused by acute Charcot foot in patients with diabetes mellitus (CHARCOT study) | |
| Phase 2Authorised | not given | Denosumab or Zoledronic acid for erosive hand osteoarthritis (EHOA) in patients with osteoporosis a randomized controlled trial (ZODIAC trial) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026